Teva Biosimilar Medicines
Teva is significantly accelerating the growth of its biosimilars business to broaden access to biologic medicines, support more sustainable healthcare systems and strengthen its position as a global biopharmaceutical company.
Teva has a 125-year legacy of delivering affordable medicine and is committed to delivering accessible biosimilars globally.
Biosimilars are highly similar to approved reference biologics and undergo rigorous regulatory evaluation to demonstrate no clinically meaningful differences in safety, purity or potency. As high-quality, cost-effective biologic treatment options, biosimilars can help ease the cost of care and provide greater access to therapy while maintaining clinical outcomes.
A broad portfolio of biosimilars
With more than 30 biosimilar products approved or in development, Teva has one of the world’s largest portfolios of biosimilars and has launched 7 biosimilars since 2020. The portfolio spans key therapeutic areas including oncology, immunology, ophthalmology and respiratory care, with 15 biosimilars in market and 16 biosimilars products in the pipeline.
With a broad portfolio, deep scientific expertise and global commercialization capabilities, Teva aims to expand access to high-quality, cost-effective biologic treatment options. Teva’s combination of innovative medicines, generics and biosimilars helps it respond to diverse patient needs and expand treatment options. 01
Combining in-house capability with strategic partnerships
Through in-house capabilities and established partnerships, Teva aims to deliver the scale and reach needed to provide more affordable biosimilars to patients. Teva has a global, fully integrated manufacturing and delivery network, with each partnership vetted to meet the same standards of scale and supply.
Global manufacturing and supply network
Manufacturing processes are validated and continually monitored to ensure performance meets the high-quality specifications required for biosimilars. Teva and its partners apply rigorous quality control throughout the manufacturing process and specific batch-release testing to assure consistent quality of biosimilars. Teva’s global manufacturing sites consistently meet the relevant regulatory standards needed to supply medicines to patients worldwide.
Committed to advancing manufacturing, Teva has state of the art facilities for manufacturing biosimilars, including a plant in Ulm, Germany, Philadelphia, USA and Israel.
Teva's top 10 pharmaceutical supply chain ranking underscores our commitment to reliable delivery of medicines worldwide.
Expanding access and supporting healthcare sustainability
Through partnerships across health systems and with one of the world's largest biosimilar portfolios, Teva is working to improve access in support of long-term healthcare sustainability.
To address the increasing prevalence of chronic diseases, Teva and its research and development partners are improving access to biosimilars for patients worldwide. Teva's expertise in complex medicines underpins our commitment to broadening access to biologics across key therapeutic areas.
Given their cost effectiveness, biosimilars can play an essential role in expanding patient access to treatment and contributing to savings for healthcare systems. Global savings from biosimilars are expected to exceed $290 billion in cumulative spending through 2027.
Teva works with health authorities, trade associations and partners across health systems to support policy environments that increase patient access to biosimilars and contribute to long-term healthcare sustainability.
Teva is also designing patient support programs that offer guidance on access, affordability and adherence. Programs are developed and delivered locally in line with relevant market needs and requirements.
A Brief History of BiopharmaceuticalsJoin us on a journey that charts where biopharmaceuticals came from and where they may be going. Discover the Magic of BiosimilarsGo behind the scenes at our lab to explore the processes involved in creating biosimilar medicines. Go behind the scenes at our lab to explore the processes involved in creating biosimilar medicines. |
Frequently asked questions about biosimilars
What are biosimilars?
A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine') in terms of structure, biological activity and efficacy, safety and immunogenicity profile. Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. 01
References
What is the difference between a generic and a biosimilar?
Generic drugs are usually synthesized from chemicals, and the manufacturing process results in an active ingredient. Biosimilars, like their reference biological products, are typically manufactured from living systems. Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. 01
References
Are biosimilars as safe and effective as the reference biologic?
Yes. Before a biosimilar is approved, it must meet strict regulatory standards showing that it is comparable to the reference biologic in efficacy, safety and immunogenicity. This helps give patients, healthcare professionals and healthcare systems confidence in its use.
What makes Teva's approach to biosimilars different?
Teva brings together long-standing pharmaceutical experience, biosimilars development expertise, reliable supply capabilities and global commercialization reach. Our aim is to help make high-quality biosimilars more available and easier to adopt with confidence.